Investment momentum surfaced across early and mid‑stage biotech: Artios closed an oversubscribed $115 million Series D to advance its DNA damage response portfolio after positive Phase I/IIa data for lead programs. The financing is aimed at accelerating clinical development for multiple DDR inhibitors and supporting combination strategies. In Europe, Sofinnova Partners closed its Capital XI fund at €650 million (~$750 million), exceeding targets and earmarked for early‑stage therapeutics and medtech investments. Sofinnova highlighted commitments to longer support cycles and operational engagement to shepherd companies through discovery to commercialization. Taken together, the financings reinforce renewed investor appetite for differentiated modalities and de‑risked clinical programs, while signaling capital availability for platform and asset‑light companies that deliver clinical validation.